All In MedTech

Device Trial Radar · NCT01812447

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema

Last checked: Nov 20, 2026Latest source record: May 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 172 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

172

Actual

Start

Jun 2013

Primary completion

Nov 2017

Study completion Aug 2022

Sponsor

Lead sponsor
Olympus Corporation of the AmericasPublic (7733.T)
Sponsor type
Industry
First posted
Mar 18, 2013

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

EMPROVE is a multicenter, prospective, randomized, controlled study designed to evaluate the safety and long-term effectiveness of the Spiration Valve System in patients with emphysema. Patients appropriate for the EMPROVE study are those who are currently on medical treatment but still symptomatic. EMPROVE also accepts α-1 antitrypsin deficiency patients.

Conditions

  • Emphysema

Interventions

  • Spiration Valve SystemDevice

    Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.

  • Medical ManagementOther

    Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary effectiveness endpoint will be the difference between the treatment and control groups in the mean change in forced expiratory volume in 1 second (FEV1)Time frame: Baseline and 6 Months

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Sparks Regional Medical Center

    Fort Smith, Arkansas

  • Kaiser Permanente Riverside Medical Center

    Riverside, California

  • University of California San Diego

    San Diego, California

31 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.